GHK-Cu: The Copper Tripeptide

The short version

GHK-Cu is a tripeptide — just three amino acids, Glycine, Histidine, and Lysine — that binds a single copper ion and travels that copper into cells that need it for repair. It occurs naturally in the body, embedded in the alpha-2(I) chain of type I collagen, and circulates in blood plasma at levels that drop noticeably as people age ^[14]. In cell and animal studies it triggers skin cells to synthesize collagen, elastin, and the structural proteins that keep connective tissue dense and resilient ^[17]. In human topical studies — small but controlled — it outperformed vitamin C and retinoic acid on stimulating new collagen production in treated subjects, and a six-month human RCT found it increased hair count versus placebo ^[13][14].

Two things to be clear about. First, most research is topical (skin-surface) and cosmetic, not injectable or systemic. Injectable and oral use of GHK-Cu is unapproved and has essentially no validated human pharmacokinetic data. Second, a large share of the foundational mechanistic literature comes from a single research group; independent replication of the broader gene-expression claims is limited ^[12]. This page covers what is established and what remains extrapolation.

What it is

GHK-Cu stands for Glycyl-L-Histidyl-L-Lysine Copper(II) complex — abbreviated GHK for the peptide portion, Cu for the copper. It is also listed in cosmetics ingredients as Copper Tripeptide-1 and appears under legacy research names such as Prezatide copper.

Structurally, it is a linear tripeptide chelated 1:1 to a Cu(II) ion. The copper binds through three coordination points: the histidine imidazole nitrogen, the glycine alpha-amino nitrogen, and the deprotonated glycine-histidine amide nitrogen. This geometry leaves the lysine side chain free, which matters for how the complex interacts with cell-surface receptors. Molecular formula: C14H23CuN6O4+ (cationic complex).

The GHK sequence is not synthetic in origin — it is found endogenously inside type I collagen. When collagen is broken down by matrix metalloproteinases (enzymes that remodel tissue), the GHK fragment is released and re-signals nearby cells to rebuild. This is thought to be part of the body's native repair loop: breakdown of old matrix releases a signal that drives new matrix synthesis ^[16].

The native GHK peptide without copper is less potent or inactive across key assays — the copper coordination is required, not optional ^[16].

How it works

GHK-Cu operates through several overlapping mechanisms. The core documented ones are:

Collagen and matrix synthesis. In human fibroblast cultures, GHK-Cu stimulated collagen synthesis at concentrations starting between 10^-12 and 10^-11 M, reaching maximum effect at 10^-9 M, without changing cell count — indicating a metabolic, not proliferative, effect ^[17]. It also stimulates dermatan sulfate, chondroitin sulfate, decorin, and elastin, building out the full structural scaffold of the dermis ^[14].

Copper-dependent cross-linking. Copper is the cofactor for lysyl oxidase, the enzyme that cross-links newly synthesized collagen and elastin fibers into mechanically stable structures. By delivering copper directly to the fibroblast, GHK-Cu enables this cross-linking step ^[16].

Antioxidant activity. Intact GHK-Cu binds copper with high stability, preventing the metal from acting as a pro-oxidant (Fenton-type chemistry). The complex also upregulates antioxidant gene sets in gene-expression analyses ^[12].

Gene expression. A 2018 analysis using Connectivity Map data reported that GHK alters expression of approximately 31.2% of human genes at a 50%-or-greater change threshold, with 59% of those genes upregulated and 41% suppressed ^[12]. The strongly upregulated sets include the ubiquitin-proteasome system (41 genes up, 1 down), DNA-repair pathways, and antioxidant genes. The often-quoted figure of "approximately 4,000 genes" is an extrapolation from broader thresholds; the verified ≥50% threshold group is on the order of 2,100 genes. These are transcriptomic signals, not confirmed protein-level outcomes in living tissue.

Angiogenesis and wound healing. GHK-Cu stimulates VEGF, FGF-2, and NGF synthesis while suppressing TGF-beta-1, TNF-alpha, and pro-inflammatory free radicals, producing a pro-healing, anti-inflammatory profile across multiple models ^[16].

Delivery challenge. The free GHK-Cu tripeptide is hydrophilic (clogP –2.24), so it penetrates skin poorly under normal conditions. A 2025 review measured roughly 0.6–2.8% copper retention through the full skin depth from standard formulations ^[11]. Strategies including palmitoylation of the peptide (Pal-GHK, clogP 1.14) and microneedle pretreatment (delivering ~134 nmol GHK through pretreated vs. zero through intact skin) substantially improve penetration ^[11].

What the research shows

Collagen synthesis — the foundational finding. In 1988, GHK-Cu was shown to dose-dependently stimulate collagen synthesis in human fibroblast cultures beginning at picomolar concentrations, without altering cell proliferation ^[17]. This anchored the mechanism and remains the most directly replicated finding.

Skin aging — topical clinical work. A 2015 review of clinical and in vitro studies found topical GHK-Cu increased collagen production in 70% of treated subjects, compared with 50% for vitamin C and 40% for retinoic acid ^[14]. Documented improvements in the same literature include skin laxity, fine lines, wrinkle depth and density, and overall clarity. Plasma GHK concentrations decline from roughly 200 ng/mL at age 20 to roughly 80 ng/mL by age 60, which is framed as part of why aging skin loses repair capacity ^[14].

Hair growth — controlled RCT. A 6-month placebo-controlled trial of 45 men with androgenetic alopecia found a 5-ALA and GHK peptide complex increased hair count by 52.6 (100 mg/mL formulation) and 71.5 (50 mg/mL formulation) versus 9.6 for placebo (p < 0.05), with no adverse events ^[13]. This is the strongest controlled human efficacy signal for a GHK-containing formulation.

Skin penetration — quantified. An ex vivo human-skin penetration study found copper applied as GHK-Cu permeated dermatomed skin with a permeability coefficient of 2.43 ± 0.51 × 10^-4 cm/h; over 48 hours, 136.2 ± 17.5 µg/cm² of copper permeated and 97 ± 6.6 µg/cm² was retained as a dermal depot ^[15]. This confirms actual transdermal delivery and depot formation, though total amounts remain limited by the clogP problem.

Gene expression — transcriptomic breadth. A 2018 gene-expression analysis mapped GHK against the Connectivity Map database and found broad transcriptomic shifts consistent with enhanced tissue-repair, DNA-repair, antioxidant and protein quality-control programs ^[12]. These findings are compelling in scope but require protein-level, in-vivo validation beyond what the database approach can provide.

Delivery advances. A 2025 review evaluated novel delivery strategies and found palmitoylation (Pal-GHK) improved clogP from –2.24 to 1.14 and microneedling pretreatment increased permeation from near-zero to ~134 nmol through treated skin — practical progress on the longstanding bioavailability limitation ^[11].

Reported effects, cautions and safety

Anecdotal, not clinical evidence. People using topical copper peptide (GHK-Cu) products in skincare communities most commonly report firmer, more taut-feeling skin after consistent twice-daily use over several weeks. Softer fine lines and shallower wrinkles are the next most-cited change, typically appearing after six to twelve weeks of regular use. A large number of users also report better hydration and a plumped, more refreshed look within the first one to two weeks. These are subjective, user-reported impressions, not controlled measurements.

Among adverse reports, skin irritation — redness, itching, dryness or stinging — is the most consistent complaint, especially in people with sensitive skin or those starting at too high a concentration. Community advice is to ease in slowly and patch-test first. A minority of users report breakouts in the first few weeks, which some describe as a transient "purging" phase. A small number report a phenomenon nicknamed the "copper uglies," where skin looks temporarily worse rather than better.

One practical incompatibility runs through nearly all community guidance: do not combine GHK-Cu with pure vitamin C, strong exfoliating acids (AHAs/BHAs), or retinol in the same application step. These actives can strip the copper from the complex or stack up irritation, effectively wasting both products. Separating them by time of day or alternating days is the standard workaround ^[11].

Documented safety cautions from the literature:

• Injectable and systemic use is unapproved and unstudied in humans. The well-documented history of topical Copper Tripeptide-1 does not transfer to injected or oral use. No validated human PK data exists for any non-topical route.
• Copper accumulation with prolonged systemic use is a theoretical concern for people with conditions affecting copper metabolism (such as Wilson's disease), though no human copper-toxicity cases tied to GHK-Cu appear in the peer-reviewed record.
• Pigmentation changes — a laboratory study showed copper peptide raised tyrosinase activity and melanin production in pigment-cell lines. People prone to melasma or dark spots may want to proceed cautiously, as individual responses vary ^[11].
• Copper coordination is required. The free GHK tripeptide without copper does not reproduce key bioactivities ^[16]. Products that separate or degrade the complex are not equivalent to GHK-Cu.
• Free copper can be pro-oxidant if the complex breaks down. Intact GHK-Cu holds copper tightly and prevents this, but degraded or destabilized products may release copper in its free, pro-oxidant form ^[16].
• Human evidence remains limited — mostly small topical studies; broader anti-aging and gene-level claims still need independent replication ^[11][12].

Where it fits in peptide chemistry

Among the three compounds on this desk, GHK-Cu has the most and the strongest human data. But that data is almost entirely topical and cosmetic — the skin-surface route is where the science lives. Its structural simplicity (three amino acids) belies how much it does: the copper ion is doing real work as a cofactor, not just as a carrier, and the sequence itself is a fragment of the body's own repair-signaling loop.

Contrast it with BPC-157, whose fifteen-amino-acid chain goes deep into the body's vascular repair machinery but has almost no controlled human data, and Ipamorelin, whose synthetic non-natural amino acids resist digestion specifically to reach a pituitary receptor. GHK-Cu is the shortest, most naturally occurring, and most human-documented of the three — a useful anchor when evaluating what "established" looks like in this field. See the comparison page for a structured side-by-side view.